Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion

Dermatology. 2010;220(4):329-32. doi: 10.1159/000278241. Epub 2010 Apr 9.

Abstract

Background: In childhood psoriasis, physicians aim for an effective and safe treatment such as with dithranol. This study presents the largest study of dithranol-treated patients described in the literature.

Objective: The aim of the study was to determine the position of dithranol in the treatment strategy for psoriasis.

Methods: All juvenile patients receiving dithranol treatment at our center were evaluated retrospectively.

Results: Sixty patients (with 82 treatment episodes in total) were included. The mean age at the start of dithranol treatment was 11.1 years (range: 3.7-17.9 years). The result of the treatment was: excellent (3.7%), good (69.5%), moderate (8.5%), reasonable (13.4%) or disappointing (4.9%). Mild irritation was seen in 39%, and severe irritation in 63% of the patients.

Conclusions: Dithranol can be regarded as an efficacious and safe topical therapy for the treatment of childhood psoriasis. It is a valuable alternative topical treatment which should not be disregarded in the treatment regimen for childhood psoriasis and should be commenced before ultraviolet or systemic treatments are initiated.

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Anthralin / therapeutic use*
  • Child
  • Child, Preschool
  • Dermatologic Agents / therapeutic use*
  • Drug Administration Schedule
  • Humans
  • Psoriasis / drug therapy*
  • Psoriasis / radiotherapy
  • Retrospective Studies
  • Treatment Outcome
  • Ultraviolet Therapy
  • Vitamin D / analogs & derivatives
  • Vitamin D / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Dermatologic Agents
  • Vitamin D
  • Anthralin